McCullough J R, Normandin D E, Conder M L, Sleph P G, Dzwonczyk S, Grover G J
Department of Pharmacology, Bristol-Myers Squibb Institute for Pharmaceutical Research, Princeton, N.J. 08543.
Circ Res. 1991 Oct;69(4):949-58. doi: 10.1161/01.res.69.4.949.
The potassium channel activators cromakalim and pinacidil were recently shown to have anti-ischemic properties in isolated globally ischemic rat hearts. The effects of two reported blockers of ATP-sensitive potassium channels, glibenclamide (glyburide) and sodium 5-hydroxydecanoate, on the anti-ischemic efficacy of cromakalim were determined in this model. Buffer-perfused rat hearts were subjected to 25 minutes of ischemia followed by 30 minutes of reperfusion. Pretreatment of these hearts with 60 microM cromakalim significantly decreased indexes of contractile function but caused a significant improvement of postreperfusion function and a significant decrease in release of lactate dehydroxygenase and in end-diastolic pressure. Pretreatment with glibenclamide at concentrations that reversed the preischemic effects of cromakalim (0.05 and 1.0 microM) also significantly reversed its postischemic protective effects. Sodium 5-hydroxydecanoate (100 and 300 microM) had no effect on the preischemic (negative inotropic) effects of cromakalim but completely reversed its cardioprotective effects. Sodium 5-hydroxydecanoate did not reverse the cardioprotective effects of the calcium entry blocker diltiazem. In phenylephrine-contracted rat aorta, glibenclamide (0.1-10 microM) inhibited cromakalim-induced relaxation, whereas sodium 5-hydroxydecanoate (10-1,000 microM) had no effect. Similarly, the ability of cromakalim to shorten cardiac action potential duration in guinea pig papillary muscle and to increase outward whole-cell potassium currents in isolated myocytes was inhibited by glibenclamide, whereas sodium 5-hydroxydecanoate was without effect. Thus, both glibenclamide and sodium 5-hydroxydecanoate inhibited the effects of cromakalim after reperfusion; however, sodium 5-hydroxydecanoate, unlike glibenclamide, had no effect in nonischemic preparations. These results suggest that sodium 5-hydroxydecanoate is an ischemia-selective inhibitor of ATP-sensitive potassium channels.
钾通道激活剂色满卡林和吡那地尔最近被证明在离体全心缺血的大鼠心脏中具有抗缺血特性。在该模型中,测定了两种已报道的ATP敏感性钾通道阻滞剂格列本脲(优降糖)和5-羟基癸酸钠对色满卡林抗缺血疗效的影响。用缓冲液灌注的大鼠心脏先进行25分钟的缺血,然后再灌注30分钟。用60微摩尔的色满卡林预处理这些心脏,可显著降低收缩功能指标,但能使再灌注后的功能显著改善,乳酸脱氢酶释放量及舒张末期压力显著降低。用能逆转色满卡林缺血前作用的浓度(0.05和1.0微摩尔)的格列本脲预处理,也能显著逆转其缺血后的保护作用。5-羟基癸酸钠(100和300微摩尔)对色满卡林的缺血前(负性肌力)作用无影响,但能完全逆转其心脏保护作用。5-羟基癸酸钠不能逆转钙通道阻滞剂地尔硫䓬的心脏保护作用。在去氧肾上腺素收缩的大鼠主动脉中,格列本脲(0.1 - 10微摩尔)抑制色满卡林诱导的舒张,而5-羟基癸酸钠(10 - 1000微摩尔)无作用。同样,格列本脲抑制了色满卡林缩短豚鼠乳头肌动作电位时程及增加离体心肌细胞外向全细胞钾电流的能力,而5-羟基癸酸钠则无此作用。因此,格列本脲和5-羟基癸酸钠在再灌注后均抑制了色满卡林的作用;然而,与格列本脲不同,5-羟基癸酸钠在非缺血制剂中无作用。这些结果表明,5-羟基癸酸钠是ATP敏感性钾通道的缺血选择性抑制剂。